Hepatic Encephalopathy – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Hepatic Encephalopathy – Pipeline Review, H1 2019’, provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy

– The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects

– The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlfaSigma SpA

Ferring International Center SA

Gilead Sciences Inc

Grifols SA

Kaleido Biosciences Inc

MallInckrodt Plc

Spherium Biomed SL

Synlogic Inc

Umecrine Cognition AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatic Encephalopathy - Overview

Hepatic Encephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hepatic Encephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatic Encephalopathy - Companies Involved in Therapeutics Development

AlfaSigma SpA

Ferring International Center SA

Gilead Sciences Inc

Grifols SA

Kaleido Biosciences Inc

MallInckrodt Plc

Spherium Biomed SL

Synlogic Inc

Umecrine Cognition AB

Hepatic Encephalopathy - Drug Profiles

albumin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GR-3027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-174 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-13019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBX-2660 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rifaximin SSD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selonsertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNB-1020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THDP-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatic Encephalopathy - Dormant Projects

Hepatic Encephalopathy - Product Development Milestones

Featured News & Press Releases

Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting

Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting 2017

Jun 01, 2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis

May 26, 2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease

Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy

Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis

Dec 07, 2016: Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy

Nov 02, 2016: Ocera Therapeutics: Update on OCR-002

Sep 19, 2016: Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy

Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)

Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology

Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy

Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hepatic Encephalopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hepatic Encephalopathy – Pipeline by AlfaSigma SpA, H1 2019

Hepatic Encephalopathy – Pipeline by Ferring International Center SA, H1 2019

Hepatic Encephalopathy – Pipeline by Gilead Sciences Inc, H1 2019

Hepatic Encephalopathy – Pipeline by Grifols SA, H1 2019

Hepatic Encephalopathy – Pipeline by Kaleido Biosciences Inc, H1 2019

Hepatic Encephalopathy – Pipeline by MallInckrodt Plc, H1 2019

Hepatic Encephalopathy – Pipeline by Spherium Biomed SL, H1 2019

Hepatic Encephalopathy – Pipeline by Synlogic Inc, H1 2019

Hepatic Encephalopathy – Pipeline by Umecrine Cognition AB, H1 2019

Hepatic Encephalopathy – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Hepatic Encephalopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports